Kynam Capital Management, LP — 13F Holdings & Portfolio
CIK 1907884 · latest 13F-HR filed 2026-08-14
Kynam Capital Management, LP manages $1.81B in 13F-reported U.S. long-equity assets across 32 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CLDX (10.95%), SNDX (9.73%), PCVX (9.39%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 5 new positions and exited 9; 18 existing positions rose in reported value and 7 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 72.7%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Apr 10, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| KELLER, JARED, JOSEPH Control | CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER since Mar 2024 | Less than 5% | Individual |
| KYNAM CAPITAL MANAGEMENT GP, LLC Control | GENERAL PARTNER since Oct 2020 | Less than 5% | Domestic Entity |
| TANG, YUE, "NMN" Control | LIMITED PARTNER since Oct 2020 | 75% or more | Individual |
| TANG, YUE, "NMN" Control Indirect owner via KYNAM CAPITAL MANAGEMENT GP, LLC | MANAGING MEMBER since Oct 2020 | 75% or more | Individual |
Ownership & leadership changes · 3 filings with changes since Apr 12, 2021
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedTANG, YUE, "NMN" · title MANAGING MEMBER → LIMITED PARTNER
- AddedKELLER, JARED, JOSEPH · CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedTANG, YUE, "NMN" · title CCO & MANAGING MEMBER → MANAGING MEMBER
- ChangedTANG, YUE, "NMN" · title MANAGING MEMBER → CCO & MANAGING MEMBER
- ListedKYNAM CAPITAL MANAGEMENT GP, LLC · GENERAL PARTNER · Less than 5% · control person
- ListedTANG, YUE, "NMN" · MANAGING MEMBER · 75% or more · control person
- ListedTANG, YUE, "NMN" · MANAGING MEMBER · 75% or more · indirect via KYNAM CAPITAL MANAGEMENT GP, LLC · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- VIRIDIAN THERAPEUTICS INC$72.8M +158.8%
- TRAVERE THERAPEUTICS INC$67.0M +143.7%
- LEGEND BIOTECH CORP$58.2M +204.0%
- UROGEN PHARMA LTD$49.2M +121.7%
- RELAY THERAPEUTICS INC$47.6M +335.7%
Top Trims
- BIOCRYST PHARMACEUTICALS INC-$28.9M -53.4%
- COGENT BIOSCIENCES INC-$13.5M -8.7%
- VERA THERAPEUTICS INC-$12.7M -9.3%
- SYNDAX PHARMACEUTICALS INC-$12.1M -6.4%
- BURNING ROCK BIOTECH LTD-$9.3M -46.9%
New Positions
- SUMMIT THERAPEUTICS INC$17.5M
- INSMED INC$10.7M
- PARABILIS MEDICINES INC$6.8M
- ENGENE THERAPEUTICS INC$792.1K
- TRAWS PHARMA INC$71.2K
Exited Positions
- KALVISTA PHARMACEUTICALS INC$36.7M
- APELLIS PHARMACEUTICALS INC$33.2M
- SOLENO THERAPEUTICS INC$18.7M
- EVOMMUNE INC$14.4M
- ENGENE HOLDINGS INC$9.2M
Kynam Capital Management, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $198.1M | 10.95% | 5,322,908 | SH |
| 2 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $176.0M | 9.73% | 8,050,959 | SH |
| 3 | VAXCYTE INC | PCVX | 92243G108 | $169.9M | 9.39% | 2,922,335 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $141.9M | 7.84% | 3,667,097 | SH |
| 5 | VERA THERAPEUTICS INC | VERA | 92337R101 | $124.0M | 6.85% | 2,890,059 | SH |
| 6 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $118.6M | 6.55% | 6,453,877 | SH |
| 7 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $113.6M | 6.28% | 2,000,000 | SH |
| 8 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $97.5M | 5.39% | 2,840,792 | SH |
| 9 | UROGEN PHARMA LTD | URGN | M96088105 | $89.6M | 4.95% | 2,434,207 | SH |
| 10 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $86.7M | 4.79% | 3,001,205 | SH |
| 11 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $81.4M | 4.50% | 21,703,093 | SH |
| 12 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $61.7M | 3.41% | 3,300,000 | SH |
| 13 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $56.7M | 3.13% | 3,114,132 | SH |
| 14 | MBX BIOSCIENCES INC | MBX | 55287L101 | $51.6M | 2.85% | 934,799 | SH |
| 15 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $43.7M | 2.41% | 1,375,000 | SH |
| 16 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $29.0M | 1.60% | 1,194,757 | SH |
| 17 | SUTRO BIOPHARMA INC | STRO | 869367201 | $29.0M | 1.60% | 872,558 | SH |
| 18 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $25.2M | 1.39% | 2,522,660 | SH |
| 19 | PHARVARIS N V | PHVS | N69605108 | $22.9M | 1.26% | 661,795 | SH |
| 20 | SUMMIT THERAPEUTICS INC | SMMT | 86627T108 | $17.5M | 0.97% | 1,200,000 | SH |
| 21 | PRELUDE THERAPEUTICS INC | PRLD | 74065P101 | $12.9M | 0.71% | 2,415,087 | SH |
| 22 | INSMED INC | INSM | 457669307 | $10.7M | 0.59% | 100,000 | SH |
| 23 | BURNING ROCK BIOTECH LTD | BNR | 12233L206 | $10.5M | 0.58% | 1,238,563 | SH |
| 24 | GERON CORP | GERN | 374163103 | $8.8M | 0.48% | 6,836,318 | SH |
| 25 | AMARIN CORP PLC | AMRN | 023111404 | $8.5M | 0.47% | 532,982 | SH |
| 26 | ALECTOR INC | ALEC | 014442107 | $7.7M | 0.42% | 3,808,494 | SH |
| 27 | PARABILIS MEDICINES INC | PBLS | 698955101 | $6.8M | 0.38% | 250,000 | SH |
| 28 | CARIBOU BIOSCIENCES INC | CRBU | 142038108 | $4.4M | 0.24% | 2,503,302 | SH |
| 29 | PROQR THRAPEUTICS N V | PRQR | N71542109 | $2.9M | 0.16% | 1,566,317 | SH |
| 30 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $996.4K | 0.06% | 96,741 | SH |
| 31 | ENGENE THERAPEUTICS INC | ENGN | 29286X101 | $792.1K | 0.04% | 457,855 | SH |
| 32 | TRAWS PHARMA INC | TRAW | 68232V884 | $71.2K | 0.00% | 84,400 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.81B | 32 | 0001907884-26-000012 |
| 2026-03-31 | 2026-05-15 | $1.62B | 39 | 0001907884-26-000007 |
| 2025-12-31 | 2026-02-17 | $1.57B | 37 | 0001907884-26-000001 |
| 2025-09-30 | 2025-11-14 | $1.34B | 35 | 0001907884-25-000002 |
PRINCETON, NJ 08540